Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

VEGF121, human recombinant

based on 1 citations in multiple journalsVEGF121, human recombinant14.1 4
A signaling protein involved in both vasculogenesis and angiogenesis
Catalog #: 4963
SKU-Size Size Price Qty
4963-10 10 μg
$180.00
4963-50 50 μg
$595.00
4963-1000 1 mg
$3,600.00
More Sizes Get Quote

Product Details

Alternate Name Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGF, MGC70609.
Gene Symbol VEGFA
Gene ID 7422
Accession # P15692
Source E. coli
Appearance Lyophilized protein
Physical Form Description Lyophilized with no additives
Molecular Weight 28.4 kDa
Purity by SDS-PAGE ≥98%
Purity by ≥98%
Endotoxin Level <0.1 ng/μg
Biological Activity Determined by the dose-dependent stimulation of the proliferation of human μmbilical vein endothelial cells (HUVEC) using a concentration range of 0.1-0.5 ng/ml.
Reconstitution Instructions Reconstitute in H₂O to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 4°C for 1 week or –20°C for future use.
Handling Centrifuge the vial prior to opening.
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not to be used in humans

Details

VEGF (Vascular Endothelial Growth Factor) is a secreted homodimeric protein, secreted by a variety of Vascularized tissues. VEGF stimulates endothelial cell growth, angiogenesis, and capillary permeability. Human VEGF is a 28.4 kDa homodimeric protein consisting of two 121 amino acid polypeptide chains.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.
Caballero, S. et. al.  Selective Blockade of Cytoskeletal Actin Remodeling Reduces Experimental Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci., Apr 2011; 52: 2490 - 2496.
For more citations of this product click here